Literature DB >> 7636667

Neuroblastoma-associated opsoclonus-myoclonus treated with intravenously administered immune globulin G.

M J Petruzzi1, P A de Alarcon.   

Abstract

An 18-month-old black girl had progressive truncal ataxia, opsoclonus, and multifocal myoclonus associated with a nonresectable abdominal ganglioneuroblastoma. Before chemotherapy, she received intravenously administered IgG, 1 gm/kg, for 2 days; within 48 hours of the first dose, there was significant improvement of the opsoclonus-myoclonus and ataxia. She required a 1 gm/kg maintenance dose every 4 to 6 weeks for a total of 12 doses, but is now free of symptomatic after 2 years with no therapy.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7636667     DOI: 10.1016/s0022-3476(95)70322-5

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  4 in total

1.  Paraneoplastic Opsoclonus-Myoclonus Syndrome: initial presentation of non-Hodgkins lymphoma.

Authors:  Ashwani Kumar; Walter A Lajara-Nanson; Robert W Neilson
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

2.  Neuroblastic tumors associated with opsoclonus-myoclonus syndrome: histological, immunohistochemical and molecular features of 15 Italian cases.

Authors:  Claudio Gambini; Massimo Conte; Gabriella Bernini; Paola Angelini; Andrea Pession; Paolo Paolucci; Alberto Donfrancesco; Edvige Veneselli; Katia Mazzocco; Gian Paolo Tonini; Lizzia Raffaghello; Carlo Dominici; Adriana Morando; Francesca Negri; Anna Favre; Bruno De Bernardi; Vito Pistoia
Journal:  Virchows Arch       Date:  2003-04-23       Impact factor: 4.064

Review 3.  Evidence for the use of intravenous immunoglobulins--a review of the literature.

Authors:  Shaye Kivity; Uriel Katz; Natalie Daniel; Udi Nussinovitch; Neophytos Papageorgiou; Yehuda Shoenfeld
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

4.  Intravenous immunoglobulin with prednisone and risk-adapted chemotherapy for children with opsoclonus myoclonus ataxia syndrome associated with neuroblastoma (ANBL00P3): a randomised, open-label, phase 3 trial.

Authors:  Pedro A de Alarcon; Katherine K Matthay; Wendy B London; Arlene Naranjo; Sheena C Tenney; Jessica A Panzer; Michael D Hogarty; Julie R Park; John M Maris; Susan L Cohn
Journal:  Lancet Child Adolesc Health       Date:  2017-11-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.